Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14) expects to post a net profit attributable to the parent of between 2.15 billion yuan and 2.39 billion yuan in 2024, soaring from 118% to 142% year on year, according to a Shanghai Stock Exchange disclosure on Monday.
The Chinese pharmaceutical company's attributable profit a year ago was 986.7 million yuan or 1.28 yuan per share.
The company attributed the forecast to a 1.71 billion yuan income generated from the disposal of a 13% stake in joint venture Sino-US Tianjin SmithKline Pharmaceutical.
Tianjin Pharma's shares rose less than 2% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。